11月肺癌月报 | 重磅研究、高分综述、新开试验,一文洞悉最新进展!

一文洞悉肺癌进展

一、 临床研究(10

NSCLC(7)
1.  N Engl J Med (IF: 74.699; Q1) 2020 Nov19.DOI: 10.1056/NEJMoa2027187
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
劳拉替尼或克唑替尼一线治疗 ALK 阳性晚期肺癌
2.  J Thorac Oncol (IF: 13.357; Q1) 2020 Nov 6.DOI: 10.1016/j.jtho.2020.10.001
Brief Report: Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination with Pegilodecakin in Patients with Metastatic Non-Small-Cell Lung Cancer (CYPRESS-1 and CYPRESS-2)
免疫检查点单药或联合Pegilodecakin 用于治疗转移性非小细胞肺癌患者的随机 2 期临床试验(CEPRESS-1 和CEPRESS-2)
3.  J Thorac Oncol (IF: 13.357; Q1) 2020 Nov25.DOI: 10.1016/j.jtho.2020.11.004
Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial
布格替尼用于既往接受过阿来替尼或其他酪氨酸激酶抑制剂的 ALK 阳性非小细胞肺癌日本患者:2 期J-ALTA 研究结果
4.  J Thorac Oncol (IF: 13.357; Q1) 2020 Nov 6.DOI: 10.1016/j.jtho.2020.09.022
Atezolizumab vs Docetaxel in Pretreated Patients with Non-Small Cell Lung Cancer: Final Results From the Randomized Phase II POPLAR and Phase III OAK Clinical Trials
阿替利珠单抗与多西他赛在经治非小细胞肺癌患者中的比较:II 期 POPLAR 和 III 期OAK 临床试验的最终结果
5.  Lancet Respir Med (IF: 25.094; Q1) 2020 Oct20.DOI: 10.1016/S2213-2600(20)30391-X
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
帕博利珠单抗联合或不联合放疗治疗转移性非小细胞肺癌:两项随机试验的合并分析
6.  J Thorac Oncol (IF: 13.357; Q1) 2020 Nov12.DOI: 10.1016/j.jtho.2020.10.129
Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14).
在局部晚期 IIIA/B 期非小细胞肺癌患者中,同步接受纳武利尤单抗和标准同步放化疗的无进展生存和总生存期:欧洲胸部肿瘤平台 NICOLAS II 期临床试验结果(ETOP 6-14)
7.  Clin Cancer Res(IF: 10.107; Q1) 2020 Nov 10.DOI:10.1158/1078-0432.CCR-20-2861
MET exon 14-altered lung cancers and MET inhibitor resistance
MET 外显子 14 改变的肺癌与 MET 抑制剂耐药性
肺部神经内分泌肿瘤1
8.  J Clin Oncol (IF: 32.956;Q1 ) 2020 Nov 2.DOI:10.1200/JCO.20.01806
Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206
伊立替康联合顺铂与依托泊苷联合顺铂治疗完全切除的高级别肺神经内分泌癌的随机III 期研究:JCOG1205/1206
SCLC2
9.  Br J Cancer(IF: 23.237; Q1) 2020 Nov 16.DOI:10.1038/s41416-020-01055-5
A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer
一项比较贝洛替康与拓扑替康单药治疗敏感复发小细胞肺癌的疗效和安全性的 2b 期随机研究
10. J ThoracOncol (IF: 13.357; Q1) 2020 Nov 6.DOI: 10.1016/j.jtho.2020.10.002
Camrelizumab Plus Apatinib in Extensive-Stage Small-Cell Lung Cancer (PASSION): A Multicenter, Two-Stage, Phase 2 Trial
卡瑞利珠单抗联合阿帕替尼治疗广泛期小细胞肺癌(PASSION):一项多中心、两阶段、2期临床试验

二、meta分析/综述(2

11. CA Cancer JClin (IF: 292.278; Q1) 2020 Nov 9. DOI: 10.1016/10.3322/caac.21650
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions
晚期实体瘤循环肿瘤 DNA:临床意义和未来研究方向
12. Cell Mol Immunol (IF: 8.484; Q1) 2020 Nov 11.DOI: 10.1038/s41423-020-00577-5
The cutting-edge progress of immune-checkpoint blockade in lung cancer
肺癌中免疫检查点抑制剂的最新进展

三、 基础研究/letters/评述(5

13. J Thorac Oncol (IF: 13.357; Q1) 2020 Nov 6.DOI: 10.1016/j.jtho.2020.09.023
Novel resistance mechanisms including L1196Q, P1094H, and R1248_D1249 insertion in three patients with non-small-cell lung cancer following ALK tyrosine kinase inhibitor treatment
在 ALK 酪氨酸激酶抑制剂治疗后 3 例非小细胞肺癌患者新的耐药机制,包括 L1196Q、P1094H 和R1248_D1249 插入
14. Clin Cancer Res(IF: 10.107; Q1) 2020 Nov 17.DOI: 0.1158/1078-0432.CCR-20-2845
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small Cell Lung Cancer
AMG757,一种长半衰期、DLL3 靶向的双特异性 T 细胞激活剂,在小细胞肺癌的临床前模型中显示出高效力和高敏感性
15. Clin Cancer Res(IF: 10.107; Q1) 2020 Nov 13.DOI:10.1158/1078-0432.CCR-20-3507
Senescent T-cells as a resistance mechanism to lung cancer immunotherapy
肺癌免疫治疗耐药机制:衰老 T 细胞
16. J Thorac Oncol (IF: 13.357; Q1) 2020 Nov 25.DOI: 10.1016/j.jtho.2020.11.006
YAP1 Expression in Small Cell Lung Cancer Defines a Distinct Subtype with T-cell Inflamed Phenotype
YAP1 表达在小细胞肺癌中定义了一个独特亚型:T 细胞炎症表型
17. Ann Oncol(IF: 18.274; Q1) 2020 Nov 22.DOI: 10.1016/j.annonc.2020.11.010
Expanding the nanotherapeutic toolbox for non-small-cell lung cancer
非小细胞肺癌纳米治疗工具的拓展

四、新开临床试验(17

NSCLC


一线治疗
二线以上治疗
辅助或新辅助
SCLC

关于NextMed数据库
NextMed是一个创新的知识数据库,专注于未满足的临床需求,收集并整合临床指南、临床试验和学术文献数据,构建起独特的适应证图谱和循证数据标准,当前收录全部肿瘤领域内的疾病、治疗、药物安全性、临床试验设计、关键临床结果等数据。NextMed已与医药魔方数据标准打通,并和NextPharma等产品形成良好数据生态,提供临床用药、适应症选择、临床研究分析、药物疗效-安全性-经济性评估等数据。
点亮“在看”,好文相伴

(0)

相关推荐